These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24103633)

  • 41. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections.
    Brinda BJ; Pasikhova Y; Quilitz RE; Thai CM; Greene JN
    J Hosp Infect; 2017 Apr; 95(4):426-432. PubMed ID: 28153556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality.
    Wu MA; Leidi F;
    Intern Emerg Med; 2017 Sep; 12(6):871-872. PubMed ID: 28681270
    [No Abstract]   [Full Text] [Related]  

  • 44. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
    Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
    Di Bella S; Nisii C; Petrosillo N
    Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
    Ford DC; Schroeder MC; Ince D; Ernst EJ
    Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report.
    Knafl D; Winhofer Y; Lötsch F; Weisshaar S; Steininger C; Burgmann H; Thalhammer F
    J Hosp Infect; 2016 Mar; 92(3):296-8. PubMed ID: 26810610
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of a Clostridium difficile infection management policy with clinical pharmacy and medical microbiology involvement at a major Canadian teaching hospital.
    Yeung SS; Yeung JK; Lau TT; Forrester LA; Steiner TS; Bowie WR; Bryce EA
    J Clin Pharm Ther; 2015 Dec; 40(6):655-60. PubMed ID: 26547905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analysis of Clostridium difficile associated diarrhea in pediatric patients with antibiotic-associated diarrhea].
    Cheng G; Li Z; Dai X; Wang Z; Cai P; Chen L; Zhang Z
    Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):220-4. PubMed ID: 26165021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clostridium difficile infection - an update].
    von Ameln-Mayerhofer A
    Med Monatsschr Pharm; 2015 Jun; 38(6):211-8; quiz 219-20. PubMed ID: 26364372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function.
    Baumgartner LJ; Brown L; Geier C
    J Pharm Pract; 2017 Dec; 30(6):650-652. PubMed ID: 27630210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.
    Manea E; Sojo-Dorado J; Jipa RE; Benea SN; Rodríguez-Baño J; Hristea A
    Clin Microbiol Infect; 2018 Feb; 24(2):180-184. PubMed ID: 28642147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
    Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.
    Van Hise NW; Bryant AM; Hennessey EK; Crannage AJ; Khoury JA; Manian FA
    Clin Infect Dis; 2016 Sep; 63(5):651-3. PubMed ID: 27318333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection.
    Sirbu BD; Soriano MM; Manzo C; Lum J; Gerding DN; Johnson S
    Clin Infect Dis; 2017 Oct; 65(8):1396-1399. PubMed ID: 28591789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Retrospective Study of Patient Factors That Indicate Provider Nonadherence to an Institutional Clostridium difficile Treatment Guideline.
    Siehnel JT; Lavigne JE; Rightmier EA; Bossard WT; Li N; Slish JC
    J Pharm Pract; 2018 Apr; 31(2):169-174. PubMed ID: 28569127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [THE EPIDEMIOLOGY OF CLOSTRIDIUM DIFFICILE INFECTIONS AND ASPECTS PERTAINING TO TREATMENT WITH VANCOMYCIN AT ASSAF HAROFEH MEDICAL CENTER].
    Youngster I; Lazarovitch T; Bondorenco M; Kachlon Y; Toledano L; Mengesha B; Zaidenstein R; Daniel C; Dadon M; Marchaim D
    Harefuah; 2018 May; 157(5):305-308. PubMed ID: 29804335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clostridium difficile infection: New insights into therapeutic options.
    Kachrimanidou M; Sarmourli T; Skoura L; Metallidis S; Malisiovas N
    Crit Rev Microbiol; 2016 Sep; 42(5):773-9. PubMed ID: 25955884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Recent epidemiology of Clostridium difficile infection in Japan].
    Yamagishi Y; Mikamo H
    Jpn J Antibiot; 2015 Dec; 68(6):345-58. PubMed ID: 27004398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
    Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
    Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.